BRIEF—MHRA authorizes Krazati as a treatment for NSCLC in adults

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today authorized a new medicine, Krazati (adagrasib), a treatment for a type of non-small cell lung cancer (NSCLC) in adults that has a mutation and produces a rare protein called KRAS G12C.

The marketing authorization was granted to a European subsidiary of US biotech Mirati Therapeutics.

Krazati can be used to treat patients with this type of NSCLC when the disease is advanced or has spread to other parts of the body, and previous treatments have failed to stop the cancer’s growth.

More than 43,000 people are diagnosed with lung cancer every year in the UK.

Non-small cell lung cancer is the most common form of lung cancer, accounting for approximately 80%-85% of cases.

Of patients with NSCLC, it is estimated that 13%-14% produce the KRAS G12C protein.